StockData
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. (ORMP) shareholders

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.71−0.32 (-7.94%)

Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
40.3%
17M of 42M shares
Institutional holders
84
29 new, 8 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 4 sales
Net sold $1.17M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Nadav Kidron3,116,7297.60%13D (active) amendmentFeb 11, 2025
BML Investment Partners, L.P.2,643,9076.55%13G (passive) amendmentDec 31, 2024
Aquamarine Financial (Cayman) Ltd2,512,1756.04%13G (passive) amendmentJun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of ORMPValueChange% of portfolio
Mercer Global Advisors Inc /Adv3,810,5409.16%$18.33M+1,900,0000.02%
Aquamarine Financial (Cayman) Ltd2,512,1756.04%$12.08M+399,8630.67%
Gem Investment Advisors, LLC1,998,8024.81%$9.61M+358,7335.89%
BlackRock, Inc.1,608,1113.87%$7.74M+1,515,9190.00%
Murchinson Ltd.1,290,2943.10%$6.21M−25,0000.86%
BML Capital Management, LLC866,2692.08%$4.17M−2,300,9622.37%
Boothbay Fund Management, LLC578,6381.39%$2.78M−22,0780.04%
Geode Capital Management, LLC500,6901.20%$2.41M+476,4080.00%
Goldman Sachs Group Inc253,2930.61%$1.22MNew0.00%
State Street Corp242,1000.58%$1.16MNew0.00%
Rathbones Group PLC233,0180.56%$1.12M−233,0180.00%
Vanguard Portfolio Management LLC229,8820.55%$1.11MNew0.00%
Dimensional Fund Advisors LP202,6090.49%$973.78K+44,4000.00%
Northern Trust Corp184,9200.44%$889.47KNew0.00%
Renaissance Technologies LLC183,8000.44%$884.08K+36,1000.00%
Wells Fargo & Company/Mn166,0000.40%$798.46K+8,4140.00%
Bank Of America Corp /De/150,6940.36%$724.84K+4,5420.00%
Strs Ohio133,8000.32%$643.58KNew0.00%
Jane Street Group, LLC113,3490.27%$545.21K+60,8090.00%
O'Shaughnessy Asset Management, LLC102,9620.25%$495.25K−13,4010.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20268417M40.3%29 / 2120 / 87M3M
Q1 20266413M32.4%16 / 1916 / 83M1M
Q4 20255713M32.1%15 / 1410 / 55M1M
Q3 2025479M22.1%5 / 910 / 52M0M
Q2 2025477M17.5%4 / 815 / 90M1M
Q1 2025528M18.7%4 / 1518 / 81M0M
Q4 2024568M18.4%9 / 1417 / 81M0M
Q3 2024557M16.7%8 / 1414 / 111M0M
Q2 2024596M14.3%10 / 1215 / 21M1M
Q1 2024515M12.9%8 / 1412 / 131M1M
Q4 2023565M12.6%9 / 1810 / 93M0M
Q3 2023562M5.5%14 / 1214 / 61M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

48 funds held ORMP in Q2 2026, 73% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of ORMPValue% of fundAs of
iShares Russell 2000 ETF634,5851.53%$3.05M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund378,4780.91%$1.54M0.00%Jul 31, 2026
iShares Russell 2000 Value ETF318,5980.77%$1.53M0.01%Jun 30, 2026
iShares Micro-Cap ETF114,9700.28%$553.01K0.04%Jun 30, 2026
Schwab Small-Cap Index Fund83,6340.20%$340.39K0.00%Jul 31, 2026
Master Small Cap Index Series63,6160.15%$305.99K0.01%Jun 30, 2026
Fidelity Small Cap Value Index Fund48,7470.12%$234.47K0.01%Jun 30, 2026
Nuveen Small Cap Blend Index Fund46,4040.11%$188.86K0.00%Jul 31, 2026
Dimensional U.S. Small Cap ETF40,4830.10%$164.77K0.00%Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF36,5360.09%$148.70K0.00%Jul 31, 2026
EQ/2000 Managed Volatility Portfolio33,5450.08%$161.35K0.00%Jun 30, 2026
Nationwide Bailard Small Cap Value Fund32,4780.08%$132.19K0.10%Jul 31, 2026
Avantis U.S. Small Cap Equity ETF28,1550.07%$111.78K0.00%May 31, 2026
LVIP State Street Small-Cap Index Fund25,7000.06%$123.62K0.01%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund24,2820.06%$96.40K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Miriam KidronChief Scientific Officer, Director2,149,5545.17%Nov 13, 2026
Nadav KidronPresident and CEO, Director5,583,50513.42%Nov 13, 2026
Joshua HexterCOO & CBO1,927,1304.63%Nov 13, 2026
Avraham GabayChief Financial Officer1,460,0763.51%Nov 13, 2026
Yehuda ReznickDirector180,8500.43%Nov 13, 2026
Arie MayerDirector242,2590.58%Nov 13, 2026
Benjamin ShapiroDirector2,097,0505.04%Nov 13, 2026
Daniel AghionDirector189,1110.45%Nov 13, 2026
Leonard SankDirector273,4200.66%Jun 9, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Yehuda Reznick
Director
Nov 12, 2026Award+2,890––180,850
Yehuda Reznick
Director
Nov 12, 2026Award+72,780––177,960
Daniel Aghion
Director
Nov 12, 2026Award+2,890––189,111
Daniel Aghion
Director
Nov 12, 2026Award+72,780––186,221
Arie Mayer
Director
Nov 12, 2026Award+1,470––242,259
Arie Mayer
Director
Nov 12, 2026Award+72,780––240,789
Benjamin Shapiro
Director
Nov 12, 2026Award+1,050––197,050
Benjamin Shapiro
Director
Nov 12, 2026Award+72,780––196,000
Nadav Kidron
President and CEO, Director
Nov 12, 2026Award+688,000––5,457,505
Nadav Kidron
President and CEO, Director
Nov 12, 2026Award+629,000––4,769,505
Miriam Kidron
Chief Scientific Officer, Director
Nov 12, 2026Award+242,000––2,149,554
Miriam Kidron
Chief Scientific Officer, Director
Nov 12, 2026Award+357,000––1,907,554
Joshua Hexter
COO & CBO
Nov 12, 2026Award+242,000––1,927,130
Joshua Hexter
COO & CBO
Nov 12, 2026Award+357,000––1,685,130
Avraham Gabay
Chief Financial Officer
Nov 12, 2026Award+242,000––1,460,076
Avraham Gabay
Chief Financial Officer
Nov 12, 2026Award+357,000––1,218,076
Avraham Gabay
Chief Financial Officer
Oct 1, 2026Sale(10b5-1 plan)−20,000$4.51$90.20K861,076
Joshua Hexter
COO & CBO
Oct 1, 2026Sale(10b5-1 plan)−30,000$4.51$135.33K1,328,130
Nadav Kidron
President and CEO, Director
Sep 24, 2026Award+349,497––3,771,740
Nadav Kidron
President and CEO, Director
Sep 24, 2026Award+368,765––4,140,505
Avraham Gabay
Chief Financial Officer
Sep 24, 2026Award+209,291––881,076
Miriam Kidron
Chief Scientific Officer, Director
Sep 24, 2026Award+208,125––1,341,263
Miriam Kidron
Chief Scientific Officer, Director
Sep 24, 2026Award+209,291––1,550,554
Joshua Hexter
COO & CBO
Sep 24, 2026Award+209,291––1,358,130
Joshua Hexter
COO & CBO
Sep 24, 2026Award+75,455––1,148,839
Joshua Hexter
COO & CBO
Jul 2, 2026Option exercise+50,000$3.69$184.50K1,073,384
Avraham Gabay
Chief Financial Officer
Jul 1, 2026Sale(10b5-1 plan)−73,360$4.51$330.85K671,785
Joshua Hexter
COO & CBO
Jul 1, 2026Sale(10b5-1 plan)−137,000$4.46$611.02K1,023,384
Miriam Kidron
Chief Scientific Officer, Director
Mar 30, 2026Tax withholding−435,084$3.31$1.44M1,133,138
Nadav Kidron
President and CEO, Director
Mar 30, 2026Tax withholding−44,818$3.31$148.35K3,422,243
Joshua Hexter
COO & CBO
Mar 17, 2026Award+95,889––1,160,384
Nadav Kidron
President and CEO, Director
Mar 17, 2026Award+167,005––3,422,243
Miriam Kidron
Chief Scientific Officer, Director
Mar 17, 2026Award+119,558––1,568,222
Avraham Gabay
Chief Financial Officer
Mar 17, 2026Award+95,889––745,145
Nadav Kidron
President and CEO, Director
Mar 12, 2026Gift−100,000––3,255,238
Nadav Kidron
President and CEO, Director
Jan 22, 2026Option exercise+109,000––3,355,238
Avraham Gabay
Chief Financial Officer
Jan 22, 2026Option exercise+19,000––649,256
Miriam Kidron
Chief Scientific Officer, Director
Jan 22, 2026Option exercise+19,000––1,448,664
Joshua Hexter
COO & CBO
Jan 22, 2026Option exercise+19,000––1,064,495
Miriam Kidron
Chief Scientific Officer, Director
Jan 14, 2026Gift−86,166––1,343,498
Benjamin Shapiro
Director
Dec 31, 2025Award+3,500––123,220
Benjamin Shapiro
Director
Dec 31, 2025Award+30,000––119,720
Nadav Kidron
President and CEO, Director
Dec 31, 2025Award+232,640––2,919,238
Nadav Kidron
President and CEO, Director
Dec 31, 2025Award+327,000––3,246,238
Yehuda Reznick
Director
Dec 31, 2025Award+30,000––98,930
Yehuda Reznick
Director
Dec 31, 2025Award+6,250––105,180
Joshua Hexter
COO & CBO
Dec 31, 2025Award+115,000––1,045,495
Joshua Hexter
COO & CBO
Dec 31, 2025Award+97,328––930,495
Arie Mayer
Director
Dec 31, 2025Award+4,900––168,009
Arie Mayer
Director
Dec 31, 2025Award+30,000––163,109
Miriam Kidron
Chief Scientific Officer, Director
Dec 31, 2025Award+115,000––1,429,664
Miriam Kidron
Chief Scientific Officer, Director
Dec 31, 2025Award+121,331––1,314,664
Avraham Gabay
Chief Financial Officer
Dec 31, 2025Award+81,216––515,256
Avraham Gabay
Chief Financial Officer
Dec 31, 2025Award+115,000––630,256
Daniel Aghion
Director
Dec 31, 2025Award+30,000––107,191
Daniel Aghion
Director
Dec 31, 2025Award+6,250––113,441
Daniel Aghion
Director
Jun 5, 2025Award+30,000––68,820
Daniel Aghion
Director
Jun 5, 2025Award+8,371––77,191
Benjamin Shapiro
Director
Jun 5, 2025Award+30,000––85,070
Benjamin Shapiro
Director
Jun 5, 2025Award+4,650––89,720

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.25%
1M shares short
Days to cover
11.3
At 0M shares a day
Change since last report
-7.4%
From 1M shares
Short volume, 20 days
51.9%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oramed Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 15,643 shares on Aug 26, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Joshua Hexter
Officer
Oct 1, 202630,000$140.10KOct 1, 2026Shares issued upon vesting of RSUs
Avi Gabay
Officer
Oct 1, 202620,000$93.40KOct 1, 2026Shares issued upon vesting of RSUs
Joshua Hexter
Officer
Jul 1, 2026137,000$658.97KJul 1, 2026Shares issued upon vesting of RSUs
Avraham Gabay
Officer
Jul 1, 202693,360$449.06KJul 1, 2026Shares issued upon vesting of RSUs

See a number that looks wrong?